Skip to content

Author

Jianchun Duan

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

PURPOSE Uncommon epidermal growth factor receptor (EGFR) mutations account for ∼10% of EGFR-altered non-small cell lung cancer (NSCLC) and show heterogeneous sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), with limited prospective evidence to inform first-line therapy. Sutetinib is an irreversible EGFR-TKI. We a...

Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.